These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 26769006)

  • 1. Effect of anti-sclerostin therapy and osteogenesis imperfecta on tissue-level properties in growing and adult mice while controlling for tissue age.
    Sinder BP; Lloyd WR; Salemi JD; Marini JC; Caird MS; Morris MD; Kozloff KM
    Bone; 2016 Mar; 84():222-229. PubMed ID: 26769006
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rapidly growing Brtl/+ mouse model of osteogenesis imperfecta improves bone mass and strength with sclerostin antibody treatment.
    Sinder BP; Salemi JD; Ominsky MS; Caird MS; Marini JC; Kozloff KM
    Bone; 2015 Feb; 71():115-23. PubMed ID: 25445450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adult Brtl/+ mouse model of osteogenesis imperfecta demonstrates anabolic response to sclerostin antibody treatment with increased bone mass and strength.
    Sinder BP; White LE; Salemi JD; Ominsky MS; Caird MS; Marini JC; Kozloff KM
    Osteoporos Int; 2014 Aug; 25(8):2097-107. PubMed ID: 24803333
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sclerostin antibody improves skeletal parameters in a Brtl/+ mouse model of osteogenesis imperfecta.
    Sinder BP; Eddy MM; Ominsky MS; Caird MS; Marini JC; Kozloff KM
    J Bone Miner Res; 2013 Jan; 28(1):73-80. PubMed ID: 22836659
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single dose of bisphosphonate preserves gains in bone mass following cessation of sclerostin antibody in Brtl/+ osteogenesis imperfecta model.
    Perosky JE; Khoury BM; Jenks TN; Ward FS; Cortright K; Meyer B; Barton DK; Sinder BP; Marini JC; Caird MS; Kozloff KM
    Bone; 2016 Dec; 93():79-85. PubMed ID: 27641475
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sclerostin antibody reduces long bone fractures in the oim/oim model of osteogenesis imperfecta.
    Cardinal M; Tys J; Roels T; Lafont S; Ominsky MS; Devogelaer JP; Chappard D; Mabilleau G; Ammann P; Nyssen-Behets C; Manicourt DH
    Bone; 2019 Jul; 124():137-147. PubMed ID: 31051315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of sclerostin antibody treatment in a mouse model of severe osteogenesis imperfecta.
    Roschger A; Roschger P; Keplingter P; Klaushofer K; Abdullah S; Kneissel M; Rauch F
    Bone; 2014 Sep; 66():182-8. PubMed ID: 24953712
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination sclerostin antibody and zoledronic acid treatment outperforms either treatment alone in a mouse model of osteogenesis imperfecta.
    Little DG; Peacock L; Mikulec K; Kneissel M; Kramer I; Cheng TL; Schindeler A; Munns C
    Bone; 2017 Aug; 101():96-103. PubMed ID: 28461254
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sclerostin Antibody Treatment Improves the Bone Phenotype of Crtap(-/-) Mice, a Model of Recessive Osteogenesis Imperfecta.
    Grafe I; Alexander S; Yang T; Lietman C; Homan EP; Munivez E; Chen Y; Jiang MM; Bertin T; Dawson B; Asuncion F; Ke HZ; Ominsky MS; Lee B
    J Bone Miner Res; 2016 May; 31(5):1030-40. PubMed ID: 26716893
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sclerostin-Antibody Treatment Decreases Fracture Rates in Axial Skeleton and Improves the Skeletal Phenotype in Growing oim/oim Mice.
    Cardinal M; Dessain A; Roels T; Lafont S; Ominsky MS; Devogelaer JP; Chappard D; Mabilleau G; Ammann P; Nyssen-Behets C; Manicourt DH
    Calcif Tissue Int; 2020 May; 106(5):494-508. PubMed ID: 32025752
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low Dose of Bisphosphonate Enhances Sclerostin Antibody-Induced Trabecular Bone Mass Gains in Brtl/+ Osteogenesis Imperfecta Mouse Model.
    Olvera D; Stolzenfeld R; Marini JC; Caird MS; Kozloff KM
    J Bone Miner Res; 2018 Jul; 33(7):1272-1282. PubMed ID: 29544018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlations Between Bone Mechanical Properties and Bone Composition Parameters in Mouse Models of Dominant and Recessive Osteogenesis Imperfecta and the Response to Anti-TGF-β Treatment.
    Bi X; Grafe I; Ding H; Flores R; Munivez E; Jiang MM; Dawson B; Lee B; Ambrose CG
    J Bone Miner Res; 2017 Feb; 32(2):347-359. PubMed ID: 27649409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brittle IV mouse model for osteogenesis imperfecta IV demonstrates postpubertal adaptations to improve whole bone strength.
    Kozloff KM; Carden A; Bergwitz C; Forlino A; Uveges TE; Morris MD; Marini JC; Goldstein SA
    J Bone Miner Res; 2004 Apr; 19(4):614-22. PubMed ID: 15005849
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Are Changes in Composition in Response to Treatment of a Mouse Model of Osteogenesis Imperfecta Sex-dependent?
    Boskey AL; Marino J; Spevak L; Pleshko N; Doty S; Carter EM; Raggio CL
    Clin Orthop Relat Res; 2015 Aug; 473(8):2587-98. PubMed ID: 25903941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alendronate treatment of the brtl osteogenesis imperfecta mouse improves femoral geometry and load response before fracture but decreases predicted material properties and has detrimental effects on osteoblasts and bone formation.
    Uveges TE; Kozloff KM; Ty JM; Ledgard F; Raggio CL; Gronowicz G; Goldstein SA; Marini JC
    J Bone Miner Res; 2009 May; 24(5):849-59. PubMed ID: 19113917
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bone matrix quality after sclerostin antibody treatment.
    Ross RD; Edwards LH; Acerbo AS; Ominsky MS; Virdi AS; Sena K; Miller LM; Sumner DR
    J Bone Miner Res; 2014 Jul; 29(7):1597-607. PubMed ID: 24470143
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cortical bone properties in the Brtl/+ mouse model of Osteogenesis imperfecta as evidenced by acoustic transmission microscopy.
    Blouin S; Fratzl-Zelman N; Roschger A; Cabral WA; Klaushofer K; Marini JC; Fratzl P; Roschger P
    J Mech Behav Biomed Mater; 2019 Feb; 90():125-132. PubMed ID: 30366302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sclerostin Antibody-Induced Changes in Bone Mass Are Site Specific in Developing Crania.
    Scheiber AL; Barton DK; Khoury BM; Marini JC; Swiderski DL; Caird MS; Kozloff KM
    J Bone Miner Res; 2019 Dec; 34(12):2301-2310. PubMed ID: 31441963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased susceptibility to microdamage in Brtl/+ mouse model for osteogenesis imperfecta.
    Davis MS; Kovacic BL; Marini JC; Shih AJ; Kozloff KM
    Bone; 2012 Mar; 50(3):784-91. PubMed ID: 22207275
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rictor is required for optimal bone accrual in response to anti-sclerostin therapy in the mouse.
    Sun W; Shi Y; Lee WC; Lee SY; Long F
    Bone; 2016 Apr; 85():1-8. PubMed ID: 26780446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.